1. Home
  2. DXCM vs KVUE Comparison

DXCM vs KVUE Comparison

Compare DXCM & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DexCom Inc.

DXCM

DexCom Inc.

HOLD

Current Price

$73.37

Market Cap

28.9B

Sector

Health Care

ML Signal

HOLD

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$19.48

Market Cap

32.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXCM
KVUE
Founded
1999
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Specialty Chemicals
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
28.9B
32.9B
IPO Year
2005
2023

Fundamental Metrics

Financial Performance
Metric
DXCM
KVUE
Price
$73.37
$19.48
Analyst Decision
Strong Buy
Buy
Analyst Count
21
11
Target Price
$85.33
$19.45
AVG Volume (30 Days)
4.1M
16.6M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
4.82%
EPS Growth
47.18
40.74
EPS
0.51
0.25
Revenue
N/A
$15,124,000,000.00
Revenue This Year
$14.46
$4.85
Revenue Next Year
$12.31
$2.63
P/E Ratio
$140.27
$77.12
Revenue Growth
N/A
N/A
52 Week Low
$54.11
$14.02
52 Week High
$82.36
$22.44

Technical Indicators

Market Signals
Indicator
DXCM
KVUE
Relative Strength Index (RSI) 52.51 59.24
Support Level $62.02 $16.83
Resistance Level $74.08 $20.13
Average True Range (ATR) 2.63 0.39
MACD -0.36 -0.04
Stochastic Oscillator 43.09 67.32

Price Performance

Historical Comparison
DXCM
KVUE

About DXCM DexCom Inc.

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Share on Social Networks: